Baidu
map

SCI REP:多巴胺D1受体激动剂可以抑制乳腺肿瘤及骨转移进展

2017-04-05 MedSci MedSci原创

在中枢神经系统中,多巴胺能信号通路扮演者重要的角色。多巴胺能信号通路参与调节认知、记忆、学习等多项功能。其功能异常与帕金森病、精神分裂症等发病息息相关。已知的多巴胺受体有D1-D5,可以分为D1类受体以及D2类受体。激动D1类受体可以诱导腺苷酸环化酶,增加细胞内cAMP水平。乳腺癌死亡首要原因并不是原发肿瘤,而是后续的肿瘤转移。其中骨转移是常见的转移方式。目前对于多巴胺能信号通路在乳腺癌及骨转移中

在中枢神经系统中,多巴胺能信号通路扮演者重要的角色。多巴胺能信号通路参与调节认知、记忆、学习等多项功能。其功能异常与帕金森病、精神分裂症等发病息息相关。已知的多巴胺受体有D1-D5,可以分为D1类受体以及D2类受体。激动D1类受体可以诱导腺苷酸环化酶,增加细胞内cAMP水平。乳腺癌死亡首要原因并不是原发肿瘤,而是后续的肿瘤转移。其中骨转移是常见的转移方式。目前对于多巴胺能信号通路在乳腺癌及骨转移中的作用研究较少。

SCI REP近期报道了一篇文章研究了乳腺肿瘤及骨转移中多巴胺能信号通路发挥的作用。研究结果表明,使用多巴胺D1受体选择性激动剂A77636抑制了乳腺癌细胞4T1.2以及MDA-MB-231的增殖。作者进一步在骨转移模型中研究了A77636对骨的作用。A77636可以促进eIF2α磷酸化下调NFATc1,抑制骨吸收破骨细胞的发展,进而抑制肿瘤细胞迁移。在骨转移鼠模型中,A77636减少了溶骨性病变,避免股骨和胫骨出现软化。

文章最后认为,多巴胺能信号通路可以为乳腺癌及骨转移的治疗提供新的治疗靶点。


原始出处:
Kazumase Minami,Shengzhi Liu,et al.Inhibitory Effects of Dopamine Receptor D1 Agonist on Mammary Tumor and Bone Metastasis.SCI REP.04 April 2017 doi:10.1038/srep45686

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2028100, encodeId=117f202810071, content=<a href='/topic/show?id=096123e95c5' target=_blank style='color:#2F92EE;'>#乳腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23795, encryptionId=096123e95c5, topicName=乳腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Apr 18 07:43:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627737, encodeId=437c162e737e5, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Apr 07 08:43:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185712, encodeId=285a185e12ae, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Fri Apr 07 08:36:36 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185455, encodeId=504d185455c5, content=宣传册才吃饭滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Thu Apr 06 06:51:31 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185362, encodeId=9a2d18536255, content=脱光光观后感, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Wed Apr 05 19:04:12 CST 2017, time=2017-04-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2028100, encodeId=117f202810071, content=<a href='/topic/show?id=096123e95c5' target=_blank style='color:#2F92EE;'>#乳腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23795, encryptionId=096123e95c5, topicName=乳腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Apr 18 07:43:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627737, encodeId=437c162e737e5, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Apr 07 08:43:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185712, encodeId=285a185e12ae, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Fri Apr 07 08:36:36 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185455, encodeId=504d185455c5, content=宣传册才吃饭滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Thu Apr 06 06:51:31 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185362, encodeId=9a2d18536255, content=脱光光观后感, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Wed Apr 05 19:04:12 CST 2017, time=2017-04-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2028100, encodeId=117f202810071, content=<a href='/topic/show?id=096123e95c5' target=_blank style='color:#2F92EE;'>#乳腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23795, encryptionId=096123e95c5, topicName=乳腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Apr 18 07:43:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627737, encodeId=437c162e737e5, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Apr 07 08:43:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185712, encodeId=285a185e12ae, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Fri Apr 07 08:36:36 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185455, encodeId=504d185455c5, content=宣传册才吃饭滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Thu Apr 06 06:51:31 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185362, encodeId=9a2d18536255, content=脱光光观后感, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Wed Apr 05 19:04:12 CST 2017, time=2017-04-05, status=1, ipAttribution=)]
    2017-04-07 tofsw

    学习了谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2028100, encodeId=117f202810071, content=<a href='/topic/show?id=096123e95c5' target=_blank style='color:#2F92EE;'>#乳腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23795, encryptionId=096123e95c5, topicName=乳腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Apr 18 07:43:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627737, encodeId=437c162e737e5, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Apr 07 08:43:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185712, encodeId=285a185e12ae, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Fri Apr 07 08:36:36 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185455, encodeId=504d185455c5, content=宣传册才吃饭滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Thu Apr 06 06:51:31 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185362, encodeId=9a2d18536255, content=脱光光观后感, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Wed Apr 05 19:04:12 CST 2017, time=2017-04-05, status=1, ipAttribution=)]
    2017-04-06 为你把脉

    宣传册才吃饭滚滚滚

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2028100, encodeId=117f202810071, content=<a href='/topic/show?id=096123e95c5' target=_blank style='color:#2F92EE;'>#乳腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23795, encryptionId=096123e95c5, topicName=乳腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Apr 18 07:43:00 CST 2017, time=2017-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627737, encodeId=437c162e737e5, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Apr 07 08:43:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185712, encodeId=285a185e12ae, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Fri Apr 07 08:36:36 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185455, encodeId=504d185455c5, content=宣传册才吃饭滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Thu Apr 06 06:51:31 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185362, encodeId=9a2d18536255, content=脱光光观后感, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Wed Apr 05 19:04:12 CST 2017, time=2017-04-05, status=1, ipAttribution=)]
    2017-04-05 为你把脉

    脱光光观后感

    0

相关资讯

J CLIN ONCOL:乳房重建1年后患者临床结局评价

乳腺癌切除术后即时乳房重建的目的是减少畸形的发生并提高患者的生活质量。JCO近期报道的一篇文章研究了乳腺癌切除术后异种植入以及自体重建的临床结局评价。

CLIN CANCER RES:口服二磷酸盐可以改善乳腺癌患者预后

二磷酸盐通常用来治疗或预防骨质疏松。全世界有数百万人服用,其中绝大多数为绝经后女性。口服二磷酸盐与乳腺癌发病风险降低有关,而且三代二磷酸盐已被证实可以有效地治疗乳腺癌患者骨转移。口服二磷酸盐是否对乳腺癌患者预后产生影响尚缺乏证据。

Am J Prev Med:有关乳腺癌和卵巢癌过度治疗,科学家有话说

据3月22日发表在美国预防医学杂志中的文章报道,通过分析BRCA诊断这项检测10年来的各种数据,研究人员发现过多的非高风险人群参加了BRCA测试,并不利于最大化其对乳腺癌或卵巢癌的检出率,呼吁医疗界不该放松基因诊断的受试门槛。

内分泌协会年会:BPS增加乳腺癌风险

一项新的研究发现,双酚S(BPS)是塑料行业中化学双酚A(BPA)的替代品,显示了通过其作为内分泌干扰化学品的行为来增加乳腺癌的侵袭性的潜力。

Cell Death & Disease:上海生科院发现肺转移性乳腺癌干细胞 并揭示其在乳腺癌转移中的作用机制

3月16日,国际学术期刊《细胞死亡和疾病》(Cell Death & Disease)在线发表了中国科学院上海生命科学研究院(人口健康领域)胡国宏研究组的最新研究成果“A CD44v+ subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity”,鉴定出了一个具有肺转移能力的乳腺癌干细胞

SCI REP:预测HR+/HER2-早期乳腺癌远处转移的新方法

激素受体阳性(HR+)乳腺癌包括HR+/HER2+以及HR+/HER2-两种,其中HR+/HER2-乳腺癌是最常见的亚型。HR+/HER2-乳腺癌患者经过激素治疗后HR+/HER2+或HR-的患者相比5年远期复发率更高。对于这类乳腺癌患者,准确评估远期复发风险对治疗有重要意义。

Baidu
map
Baidu
map
Baidu
map